The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Metro Bank Down Amid Mortgage Competition

Wed, 24th Oct 2018 10:43

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - WINNERS----------Barclays, up 0.9%. The bank reported a rise in third quarter profit but year-to-date profit remained lower, dragged by litigation costs and conducts charges experienced earlier in the year.For the three months ended September, Barclays pretax profit increased sharply to GBP1.46 billion from GBP1.11 billion in the third quarter of 2017. The improvement was led by Barclays investment bank, which helped the Barclays International division to a 30% rise in profit. The group raised its third quarter dividend to 2.5 pence from 1.0p paid a year before. Barclays reiterated its intention to pay a total dividend of 6.5p for 2018.----------International Consolidated Airlines Group up 1.5%. Deutsche Bank raised is rating on European Airlines sector to Overweight from Underweight. easyJet was up 0.5%.----------FTSE 100 - LOSERS----------Fresnillo, down 2.7%. The gold miner revised its annual production guidance after having mixed results in the third quarter. The company said gold production in the three months to the end of September 30 declined by 3.5% to 225,000 ounces, while silver production increased by 6.3% year-on-year to 15.5 million ounces. However, Fresnillo said third-quarter silver production was not as high as anticipated and reduced its annual guidance for silver output to between 62.0 million and 64.5 million ounces from 64.5 million to 67.5 million ounces estimated earlier. Fresnillo now expects to produce between 920,000 and 940,000 ounces of gold in the full year, up from 900,000 to 930,000 ounces guided previously. Fellow gold miner Randgold Resources was down 1.7%.----------FTSE 250 - WINNERS----------Equiniti, up 0.6%. The payments services provider won two pension administration contracts in the UK nuclear sector. Under the terms of the contracts, Equiniti's pension division, EQPaymaster, will support virtually all employees and former employees engaged in the UK nuclear industry. The contracts are for the UK Atomic Energy Authority and for the Combined Nuclear Pension Plan, covering 60,000 members in total.----------FTSE 250 - LOSERS----------Metro Bank, down 7.9%. The challenger bank said it is experiencing continued competition in residential mortgages resulting in "slowed margin progress". Net interest margin fell by 15 basis points to 1.82%. More positively, Metro Bank reported lending growth of 52% in the first nine months to GBP13.12 billion from GBP8.61 billion, with commercial loans up 43% to GBP4.17 billion and residential mortgages up 59% to GBP8.72 billion. Underlying pretax profit multiplied to GBP39.2 million from GBP13.2 million, while statutory pretax profit jumped to GBP25.1 million from GBP7.8 million. At the end of the period, the bank's assets stood at GBP20.57 billion, up 41% year-on-year, while its loan to deposit ratio grew to 89% from 80%. Its Common Equity Tier 1 Capital ratio remained robust at 15.7% as at September-end. ----------Stobart Group, down 5.4%. The infrastructure & support services company swung to a loss in the first half of its financial year, despite a 21% increase in revenue. For the six months to August 31, Stobart reported a pretax loss of GBP18.8 million compared with a GBP111.6 million profit in the same period a year ago. Interim revenue increased to GBP151.3 million from GBP124.6 million year-on-year. The company's profit was hurt by the lack of income generated by the sale of its 49% interest in the parent of Eddie Stobart, Greenwhitestar Holding Co 1, which resulted in a GBP123.8 million profit figuring in its interim balance sheet a year ago. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Photo-Me International, up 10%. The photo-booth operator maintained its annual guidance following the completion of restructuring of its Japanese unit. Photo-Me said it removed unprofitable machines and installed new ones with a "significantly" lower production cost. As a result, the company expects to have a 35% faster return on its Japanese investment. Photo-Me said its deployment of encrypted photo ID upload technology has "continued to progress well", with 2,700 photo booths in the UK now enabled for UK passport renewals. The company is now targeting the deployment of 4,000 enabled photo booths by the end of December.----------OTHER MAIN MARKET AND AIM - LOSERS----------Yu Group, down 83%. The gas & electricity supplier said it expects a GBP10 million reduction in profit, which will send it to a loss, after discovering areas of concern in a performance review. One of the areas of concern for the group was the recognition of historic accrued income, which totalled GBP4.2 million for 2017 and GBP4.3 million for the six months to June. The level of trade debtors held also caused concern to the group, as if found that the level of non-payment being experienced is "significantly above that which has been previously provided for". Looking ahead, despite being "extremely disappointed" to reveal the profitability drop, Yu said it expects to achieve a profit in 2019. ----------Scancell Holdings, down 15%. The biopharmaceutical company said the US Food & Drug Administration has asked for further information on its SCIB1 product's proposed trial. Scancell applied for an investigational new drug application to the FDA for SCIB1, which will be trialled in combination with pembrolizumab in patients with advanced melanoma. The trial is being carried out alongside Ichor Medical Systems Inc's TriGrid electroporation delivery system, and it is further information on this that the US regulator has asked for. The system, Scancell said, has been used on the previous SCIB1 phase 1/2 stud, which had favourable results.----------
More News
22 Jul 2020 11:24

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

IN BRIEF: Scancell To Raise GBP15 Million Via Share, Loan Note Issue

Read more
24 Jun 2020 12:18

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Scancell To Start Clinical Trial For Cancer Treatment In 2021

Read more
12 Jun 2020 12:59

Scancell upbeat on publication of AvidiMab research

(Sharecast News) - Cancer immunotherapy developer Scancell Holdings noted the publication of its manuscript in Cancer Research, a journal of the American Association of Cancer Research (AACR) on Friday, titled 'Engineering the human Fc-region enables direct cell killing by cancer glycan-targeting antibodies without the need for immune effector cells or complement'.

Read more
28 Apr 2020 16:40

Director dealings: Scancell director lowers stake

(Sharecast News) - Scancell revealed on Tuesday that non-executive director Martin Diggle had sold 1.5m ordinary shares in the AIM-listed biotechnology firm.

Read more
28 Apr 2020 14:43

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

UK DIRECTOR DEALINGS SUMMARY: Citrus Buys More easyHotel At Exit Price

Read more
24 Apr 2020 12:00

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Scancell Rises On Launch Of Covid-19 Vaccine Research Programme

Read more
24 Apr 2020 10:49

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

UK WINNERS & LOSERS SUMMARY: FirstGroup Rises On Liquidity Boost

Read more
3 Feb 2020 14:20

Scancell's 'SCIB1' clears latest regulatory hurdle in US

(Sharecast News) - Cancer immunotherapy developer Scancell announced on Monday that its investigational new drug (IND) application to the United States Food and Drug Administration (FDA) for 'SCIB1' has been approved.

Read more
3 Feb 2020 10:44

Scancell Gets US FDA Approval For SCIB1 Drug Application

Scancell Gets US FDA Approval For SCIB1 Drug Application

Read more
31 Jan 2020 11:12

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Scancell Interim Loss Narrows, Progresses On Product Pipeline

Read more
20 Jan 2020 12:04

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Scancell Teams To Evaluate Its Antibody Platform For Cancer Treatment

Read more
18 Dec 2019 16:29

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

DIRECTOR DEALINGS: Scancell Non-Executive Diggle Buys 3 Million Shares

Read more
16 Dec 2019 13:30

Scancell inks AvidiMab agreement with Chinese biotech company

(Sharecast News) - Scancell Holdings on Monday signed a collaboration and non-exclusive research agreement with an unnamed Chinese biotechnology firm.

Read more
16 Dec 2019 09:21

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Scancell Shares Jump As It Secures First Deal In China For AvidiMab

Read more
12 Dec 2019 14:23

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Oxford Technology VCTs Report Mixed Third-Quarter Performances

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.